Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 5/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | DDO | Q99489 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8686734 | 0.82 | PARP1 (0.51) | PARP1DAOATMNPSR1LMNA | |
| SCHEMBL26247290 | 0.79 | AR (0.45) | ARPARP1PGRROCK2NAMPT | |
| SCHEMBL26615075 | 0.79 | AR (0.45) | ARPARP1DAOPGRROCK2 | |
| SCHEMBL31690178 | 0.79 | AR (0.45) | ARPARP1PGRROCK2NAMPT | |
| SCHEMBL30319337 | 0.78 | AR (0.41) | ARPARP1ROCK2NAMPT | |
| SCHEMBL13145722 | 0.77 | AR (0.43) | ARPARP1PGRROCK2NAMPT | |
| SCHEMBL13180318 | 0.76 | AR (0.52) | ARPARP1LMNA | |
| SCHEMBL14158228 | 0.74 | GPR84 (0.39) | ARPARP1DAODDOFEN1 | |
| SCHEMBL765469 | 0.74 | ATM (0.57) | ARPARP1ATMNPSR1LMNA | |
| SCHEMBL26615088 | 0.72 | AR (0.49) | ARPARP1ROCK2NAMPTTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2325169-B1 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | Univ Virginia Patent Found (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2325169-A9 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | University Of Virginia Patent Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2325169-A2 | Lisofylline analogues and their pharmeacuetical uses | University Of Virginia Patent Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| WO-2008108842-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007027719-A2 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | AR 4864/4885PARP1 3921/4885DAO 1201/4885 |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | AR 4880/4885PARP1 2471/4885DAO 1895/4885 |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | AR 4876/4885PARP1 2787/4885DAO 1919/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | AR 4876/4885PARP1 2787/4885DAO 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.